Unilabs A/S

Ledelsesberetning

Key activities The primary activity of the Company is to support drug development as a leading provider of laboratory services and solutions for the pharmaceutical and biotechnology industries. The Company conducts bioanalytical testing that supports clinical trials and post-market surveillance, ensuring that new therapies are developed efficiently and comply with regulatory requirements. Development in the year The income statement of the Company for 2024 shows a profit of TDKK 44,593, and at 31 December 2024 the balance sheet of the Company shows a positive equity of TDKK 52,324. The past year and follow-up on development expectations from last year In 2024, the company’s turnover increased by 2%, driven primarily by two key factors. Firstly, there was a notable increase in project volume from existing, long-term customers who continued to place their trust in the company’s capabilities. Secondly, a wave of new customers was onboarded, largely as a result of the company's strong track record in clinical trial execution and its growing reputation within the drug development sector. This expansion was underpinned by successful progression of several molecules in the pipeline into later stages of clinical development, which, in turn, created additional demand for the company’s specialized support services. The improved momentum in the clinical pipeline was closely linked to the company's ability to deliver high-quality, compliant, and timely project outcomes. Customers increasingly relied on the company to provide expanded analytical, regulatory, and project management support, contributing positively to both turnover and long-term strategic partnerships. In parallel, gross profit per project also showed a year-over-year improvement. This encouraging development reflects the impact of targeted initiatives launched to enhance project delivery performance and resource efficiency. Through structured efforts in resource planning, capacity alignment, and cross-functional collaboration, the company succeeded in improving both the cost base and execution quality. While variability in project composition and timelines remains a factor, the general trend towards improved profitability per engagement indicates solid progress in operational effectiveness. The profit for the year was higher than expected due to the combined effect of increased customer demand, successful project execution, and cost optimization initiatives. This performance not only exceeded internal forecasts but also reinforced the robustness of the company’s operational model. Additionally, the organizational changes initiated in 2023 started to yield tangible benefits in 2024. A more streamlined and cost-conscious organizational structure, combined with refined role definitions and team accountability, led to a measurable reduction in personnel costs. These efforts not only enhanced cost efficiency but also helped foster a more agile and delivery-focused company culture. Looking ahead, the positive financial and operational developments of 2024 lay a strong foundation for continued growth and strategic positioning within the competitive landscape of drug development services. The company during 2024 paid an extraordinary dividend of DKK 160,000k. Targets and expectations for the year ahead The focus is on maintaining the current business within pharma and biotech, supporting drug development projects, and monitoring patients in 2025. Focus on improving operational efficiency and achieving commercial excellence to secure new business. The company expects revenue and profit for the coming year to be TDKK 32,969. Aim to build a sustainable Pharma Solutions business within the Unilab's network, enhancing lab connectivity to streamline workflow, reduce silos, and offer unified services. The long-term strategy is to become a global leader in speciality lab testing for pharma, specializing in drug development, gaining reputation and market share. Intellectual capital resources The Company’s knowledge of clinical biochemistry and regulated biomarker analysis is vested in the Company’s employees. Unilabs has many skilled employees across its international laboratories supporting pharma drug development projects. The international approach ensures a robust capacity to deliver and reduces exposure to local changes in a given laboratory. The Company’s knowledge of clinical biochemistry and regulated biomarker analysis is vested in the Company’s employees. Unilabs has many skilled employees across its international laboratories supporting pharma drug development projects. The international approach ensures a robust capacity to deliver and reduces exposure to local changes in a given laboratory.